The Australian Phenylketonuria Therapeutics Market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Phenylketonuria (PKU) is a genetic disorder that prevents the normal breakdown of a protein found in some foods. Proteins are made up of building blocks called amino acids; in PKU, the body cannot break down the amino acid phenylalanine. Because phenylalanine cannot be broken down (metabolised) normally, it builds up in the blood and tissues. This build-up prevents the brain from developing properly. Progressive intellectual disability results if PKU is not treated from early infancy. With treatment, children with PKU can grow and develop normally. People with PKU need to follow a diet that limits foods with phenylalanine. The diet should be followed carefully and be started as soon after birth as possible. Food mainly suggested are Milk and cheese, Eggs, Nuts, Soybeans, Beans, Chicken, beef, or pork, Fish, Peas, Beer.
Phenylketonuria (PKU) affected approximately 1,600 Australians & it is estimated that 1 in every 15,000 newborn babies in Australia will have PKU. Parents of a child with PKU have a one in four chance of having another child with the debilitating condition.
In recent years, small and large pharmaceutical and nutraceutical companies have become increasingly dependent on contract research organizations (CROs) and other clinical services to provide research services to their R&D operations. However, Phenylketonuria treatment based products, including protein ingredients as well as finished products, are expected to drive market growth. Rising demand for essential and nonessential amino acids in the form of protein ingredients as well as finished product has led Australia to generate more than 80% of the revenue share in the Phenylketonuria Therapeutic market.
However, rising treatment costs and lack of awareness among patients and physicians about Phenylketonuria are among the major factors acting as restraints, and will continue to pose a challenge to the Phenylketonuria (PKU) Therapeutic market in the forecast period.